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Abstract
Background:  Delay in tuberculosis diagnosis and treatment initiation may increase disease
severity and mortality. In evaluations of tuberculosis control programmes high fatality rates during
tuberculosis treatment, are used as an indicator of long delays in low HIV-prevalence settings.
However, data for this presumed association between delay and fatality are lacking. We assessed
the association between diagnostic delay and mortality of new smear-positive pulmonary
tuberculosis patients in Vietnam.
Methods: Follow-up of a patient cohort included in a survey of diagnostic delay in 70 randomly
selected districts. Data on diagnosis and treatment were extracted from routine registers. Patients
who had died during the course of treatment were compared to those with reported cure,
completed treatment or failure (survivors).
Results: Complete data were available for 1881/2093 (89.9%) patients, of whom 82 (4.4%) had
died. Fatality was 4.5% for patients with ≤ 4 weeks delay, 5.0% for 5- ≤ 8 weeks delay (aOR 1.11,
95%CI 0.67–1.84) and 3.2% for > 9 weeks delay (aOR 0.69, 95%CI 0.37–1.30). Fatality tended to
decline with increasing delay but this was not significant. Fatality was not associated with median
diagnostic delay at district level (Spearman's rho = -0.08, P = 0.5).
Conclusion: Diagnostic delay is not associated with treatment mortality in Vietnam at individual
nor district level, suggesting that high case fatality should not be used as an indicator of long
diagnostic delay in national tuberculosis programmes.
Background
Worldwide around 2 million people die with tuberculosis
each year [1]. Of all new smear-positive pulmonary tuber-
culosis patients treated in programmes applying the
World Health Organization's (WHO) DOTS strategy,
4.6% died [1].
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It is generally assumed that delay in diagnosis and treat-
ment initiation increases the severity of disease at the time
of diagnosis and the risk of death [2,3]. This assumed rela-
tion is often reason to measure the length of delays before
tuberculosis treatment [4-6]. Conversely, a high case fatal-
ity, i.e. death during the course of tuberculosis treatment,
is often perceived to reflect long delays in low HIV-preva-
lence settings. In program evaluations high case fatality
rates are thereby used as an indicator of low access to clin-
ics [7].
With time, tuberculosis disease progresses [8] and chances
of survival will decline. With worsening and spreading of
pulmonary tuberculosis lesions the bacillary load in the
lungs generally increases [8]. Therefore, longer delays
could lead to more progressed disease with higher bacil-
lary loads in sputum, which could result in higher fatality.
Delayed treatment was strongly associated with death in a
study carried out in Canada [9], and with death among
HIV-positive patients, but not among HIV-negative
patients, in a study from New York City [10]. Delay in
seeking treatment was not an independent predictor for
tuberculosis mortality during on average 2.3 year period
after diagnosis in Mexico [11]. A study from South Africa
showed that those who survived had a significant shorter
median treatment delay than those who had died [12].
However, this study used treatment delay instead of total
delay. Treatment delay is the time period from first seek-
ing help for symptoms until treatment initiation. There-
fore, treatment delay is a fraction of the total diagnostic
delay, i.e. the time period from onset of tuberculosis
symptoms to treatment initiation. Therefore, total diag-
nostic delay is possibly a better indicator of the duration
of illness than treatment delay. In high-burden tuberculo-
sis settings, no studies have been carried out on the asso-
ciation of total diagnostic delay with tuberculosis
mortality.
Vietnam has a high burden of tuberculosis, with 58,389
new smear-positive tuberculosis patients notified in 2004
(70/100,000 population) [1]. The DOTS strategy has been
implemented nationwide since 2000 [13]. Treatment out-
comes of 90% cure and 3.4% death for new smear-posi-
tive tuberculosis cases in 2002 were reported by the
National Tuberculosis Control Programme Vietnam
(NTP) [14]. The prevalence of HIV infection in the adult
population was 0.5% in 2005 (range 0.3–0.9%) [15].
Mean diagnostic delay was 7 weeks and 15% of patients
had reported a delay of 12 weeks or more in 2002 [16].
As data for the presumed association between delay and
fatality are lacking, it is unknown whether fatality can be
used as an indicator for long delays in programme evalu-
ations. This study aims to assess the association between
total delay and fatality of new smear-positive pulmonary
tuberculosis patients in a programmatic ambulant setting
in Vietnam.
Methods
A cohort of 2,093 patients with newly diagnosed smear-
positive tuberculosis was followed who were included in
a survey of diagnostic delay carried out in 2002. That
study included all patients consecutively registered for
treatment over a period of 3 months in 70 randomly
selected districts in Vietnam. Study population and meth-
ods are described elsewhere [16]. Diagnostic delay was
defined as the period between the onset of cough and
treatment initiation. Patients were interviewed using a
pre-coded structured questionnaire including demo-
graphic variables; time period between onset of cough
and treatment initiation; date of diagnosis; starting date of
treatment. The district tuberculosis coordinators were
trained on performing interviews and interviewed
patients within 2 weeks of treatment registration.
Case definitions of the NTP follow international recom-
mendations [17].
Included were patients aged ≥ 15 years, registered as new
smear-positive pulmonary tuberculosis with registered
treatment outcome of cure, treatment completion, failure
or death following treatment with the standard NTP regi-
men of short-course chemotherapy (SCC) for new smear-
positive pulmonary tuberculosis. This regimen contains
daily streptomycin, isoniazid, rifampicin and pyrazina-
mide for 2 months, followed by daily isoniazid and
ethambutol for 6 months (2SHRZ/6HE). To avoid mis-
classification, we excluded patients with an unknown sur-
vival status, i.e. patients with a registered treatment
outcome of default or transfer-out or unevaluated treat-
ment outcome.
An indicator of the bacillary load in the sputum is the spu-
tum grade at diagnosis [18], which is a grading of the
reported number of acid-fast bacilli found in a defined
number of immersion fields of a Ziehl-Neelsen stained
sputum smear [19]. The NTP has a standard recording and
reporting system for smear examination [20]. Classifica-
tion of sputum grade of the NTP follows international rec-
ommendations [21]. The NTP's laboratory quality control
system reports 99% concordance between smear reading
in the tuberculosis clinics and rereading in provincial lab-
oratories [22].
Data on diagnosis, treatment monitoring and outcome
were extracted from routine laboratory and treatment reg-
isters. A pre-coded and pre-tested structured form
included information on date of treatment initiation,
treatment regimen, treatment outcome, date of treatmentBMC Public Health 2007, 7:210 http://www.biomedcentral.com/1471-2458/7/210
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completion or death and Ziehl-Neelsen stain grade at
diagnosis and at 2, 5 and 8 months. Blinded to the origi-
nal forms, information on 10% of randomly selected
patients was double collected from routine registers and
checked for inconsistencies (1.7% of items).
The research board of the National Hospital for Tubercu-
losis and Respiratory Diseases, Hanoi gave scientific and
ethical clearance for the study.
Death as treatment outcome or fatality is defined as death
due to any cause during the course of treatment [17].
Death directly due to tuberculosis most likely occurs dur-
ing the first months of treatment [23] and therefore early
mortality was defined as a reported death within 3
months after treatment initiation.
Data were entered using Epi Info 2002 and a 10% ran-
domly selected sample of forms were re-entered in
blinded fashion, resulting in inconsistencies of data entry
in 0.22% of items. Analyses were performed using Stata/
SE V8.0 (Stata Corp., College Station TX, USA).
The analysis was restricted to patients with known vital
status at the end of treatment. Survival was defined as a
reported treatment outcome of cure, treatment comple-
tion or treatment failure. Survival cases were compared to
patients with reported death. The sputum grade at diagno-
sis was calculated as the highest reported sputum grade
observed in the examined smear slides.
Survival time was calculated as the time interval from date
of treatment initiation to the date of treatment outcome.
Survival curves up to 4 months after treatment initiation
were constructed for three classes of diagnostic delay
using the Kaplan-Meier method.
As diagnostic delay as a continuous variable was not nor-
mally distributed, it was transformed by taking its natural
logarithm (Ln).
To assess differences at the 5% significance level, two-
sided Fisher's exact test or Chi-square tests were used.
Primary analyses included logistic regression on fatality
during the total course of tuberculosis treatment. The
multivariate model was built as follows. Apart from diag-
nostic delay, age was thought to be associated with fatality
and thus included in the multivariate model. Other varia-
bles and interaction terms were included if the term con-
tributed to the model with a p value < 0.10. If the p-value
of a covariate or interaction term was < 0.1 and con-
founded the association between delay and fatality, we
decided it contributed to the model, and it was included
in the final model.
Secondary analyses included survival analyses on early
fatality. The risk of early fatality was compared between
subgroups to identify risk factors. Cox proportional haz-
ard modelling was used for adjustment of confounders.
Correlation on district level between mean and median
diagnostic delay and fatality was analysed using Spear-
man's rho. Fatality was the proportion of deaths of all
who started treatment in a district in 2002 and 2003 as
reported by the quarterly reports of that district.
Results
Of 2,093 eligible patients, this study included 1,881
patients (89.9%) of whom 82 (4.4%, 95%CI 3.5–5.4%)
had died (Figure 1).
Among excluded subjects male sex and older age were
more common than among included subjects (Table 1).
Characteristics of patients by survival status are described
in Table 2. Mean and median delay were 5.6 (SD 4.5) and
4 weeks (inter-quartile range (IQR) 3–7) for patients who
died. These were 7.2 (SD 9.1) and 4 weeks (IQR 3–8) for
patients who survived. Fatality did not increase with
longer diagnostic delay at the individual level (Figure 2).
At the level of districts, fatality did not correlate with
mean or median diagnostic delay (Spearman's rho = -
0,08, P = 0.5) (Figure 3).
Fatality declined, but not significantly, with increasing
delay in the crude and adjusted analyses (aOdds Ratio
(OR) 0.78 per log delay-week) (Table 2). Fatality was low-
est with 3.2% for those with diagnostic delays > 9 weeks,
but did not significantly differ from delay ≤ 4 weeks (aOR
0.69) (Table 2).
In Vietnam HIV prevalence is highest among young adults
and reported long delays may be most prone to recall bias.
Results were very similar for the crude and adjusted OR for
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delay as a continuous and as a categorical variable after
excluding patients with extreme delays of ≥ 27 weeks or
patients aged < 35 years from the analyses. Therefore,
young patients and extreme delays did not explain the
lack of an expected increase in fatality with diagnostic
delay. We therefore included these subjects in the analysis.
Of 82 deaths, 40 occurred ≤ 3 months after treatment ini-
tiation and had available data on survival time (2.2%,
95%CI 1.6–3.0%). Survival was not higher for those with
delay > 9 weeks compared to those with delay ≤ 8 weeks
(HR 0.42, 95%CI 0.15–1.17) (Figure 4). The unadjusted
hazard for early mortality declined significantly with 0.62
(95%CI, 0.41–0.96) per Ln(delay-week). This was not
affected by adjustment for age, sex or sputum grade. The
hazard ratio (HR) was lowest with 0.40 for those with
delay > 9 weeks. The difference with delay ≤ 4 weeks was
not significant.
Sputum grade at diagnosis may be on the causal pathway
between diagnostic delay and death, and we tested these
associations. Sputum grade at diagnosis differed signifi-
Table 2: Survival status by risk factors among new smear-positive tuberculosis patients
Survival N Death N (%) P value Crude OR (95%CI) Adjusted* OR 
(95%CI)




1799 82 (4.4%) 0.77 (0.57–1.03) 0.78 (0.58–1.05)
≤ 4 weeks 931 44 (4.5%) 1 1
5- ≤ 8 weeks 479 25 (5.0%) 1.10 (0.67–1.83) 1.11 (0.67–1.84)
> 9 weeks 389 13 (3.2%) 0.71 (0.38–1.33) 0.69 (0.37–1.30)
Sex 0.138
Men 1262 64 (4.8%) 1 1
Women 537 18 (3.2%) 0.66 (0.39–1.13) 0.58 (0.34–1.00)
Age, years 0.010
15–34 470 20 (4.1%) 1 1
35–54 731 22 (2.9%) 0.71 (0.38–1.31) 0.68 (0.37–1.27)
≥ 55 598 40 (6.3%) 1.57 (0.91–2.7) 1.64 (0.37–1.27)
Sputum grade at 
diagnosis (n = 1,827)
0.256
Scanty 119 10 (7.8%) 2.1 (1.01–4.2) 2.1 (1.02–4.3)
1+ 1028 42 (3.9%) 1 1
2+ 370 18 (4.6%) 1.19 (0.68–2.1) 1.22 (0.69–2.2)
3+ 230 7 (4.2%) 1.06 (0.53–2.2) 1.14 (0.56–2.3)
* Adjusted for age group, diagnostic delay and sex
OR = Odds Ratio
† Log transformation
Table 1: Characteristics of in- and excluded subjects in the study
All Included N (%) Excluded N (%) p
All 2093 1881 (89.9%) 212 (10.1%)
Diagnostic Delay 0.196
≤ 4 weeks 1059 975 (92.1%) 84 (7.9%)
5- ≤ 8 weeks 561 504 (89.8%) 57 (10.2%)
> 9 weeks 448 402 (89.7%) 46 (10.3%)
missing 25 0 25
Sex 0.0038
Men 1491 1326 (88.9%) 165 (11.1%)
Women 596 555 (93.1%) 41 (6.9%)
Age, years 0.006
15–34 515 490 (95.1%) 25 (4.9%)
35–54 823 753 (91.5%) 70 (8.5%)
≥ 55 715 638 (89.2%) 77 (10.8%)BMC Public Health 2007, 7:210 http://www.biomedcentral.com/1471-2458/7/210
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cantly by diagnostic delay (P = 0.008). However, no clear
pattern was observed in the association of sputum grades
with diagnostic delay (data not shown). A scanty sputum
grade at diagnosis was significantly associated with fatal-
ity (aOR 2.1), but higher sputum grades at diagnosis were
not (Table 2). Results for the association of diagnostic
delay with fatality were very similar after adjustment for
sputum grade at diagnosis (data not shown).
Discussion
We hypothesized that high mortality rates would indicate
long diagnostic delay. This study showed that mortality
during tuberculosis treatment did not increase with diag-
nostic delay on individual and district level; if anything,
there was a trend towards shorter delay. This association
was not explained by age, sex or sputum grade at diagno-
sis.
Death as a result of tuberculosis pathology is most likely
to occur during the first months after treatment initiation.
During the initial phase of treatment (2 or 3 months) a
rapid stop is put to bacterial multiplication, which limits
further deterioration and death after the first weeks of
treatment initiation [23]. The numbers of bacilli are low
in the continuation phase [24] and causes of death other
than tuberculosis play a greater role. However, early fatal-
ity did also not increase with diagnostic delay.
These study results do not confirm findings from Canada
[9]. Possible explanations are differences in progression
rates between patients or in influence of co-morbidity on
progression rates and mortality, or biased results due to
study limitations.
Progression from infection to tuberculosis disease as well
as the severity of disease may differ between subjects.
Increasing delay may lead to increasing mortality if dis-
ease progresses in a similar way across the total study pop-
ulation. However, some patients may have rapid disease
progression and in these patients short delay may be asso-
Kaplan-Meier survival curve for the first 4 months after treat- ment initiation for 1,759 surviving and 74 deceased patients  by duration of diagnostic delay Figure 4
Kaplan-Meier survival curve for the first 4 months after treat-
ment initiation for 1,759 surviving and 74 deceased patients 
by duration of diagnostic delay.
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ciated with high mortality. Patients with rapid progres-
sion cannot be differentiated from patients with slow
progression in this study nor in programmatic settings.
Possibly the proportion of patients with rapid progression
outweighs the proportion of patients with regular or slow
progression of tuberculosis. Differing progression rates
between patients implies that mortality cannot be used as
an indicator of long delays.
The prevalence of co-morbidity may differ by setting.
Tuberculosis patient may suffer simultaneously from
other diseases, such as malignancies, diabetes or HIV
which can affect the development of tuberculosis and
mortality both [25]. For instance, HIV-infection is a strong
risk factor for death during tuberculosis treatment [26,27]
and HIV-infection increases the rate of progression from
infection to disease [26]. Therefore, co-morbidity may
have modified the effect of delay on mortality. Co-mor-
bidity as a risk factor for development of tuberculosis is
probably more common among patients in a low inci-
dence tuberculosis setting or in a high HIV-prevalence set-
ting. For instance, the estimated prevalence of diabetes
was with 7.5% in Canada higher than in Vietnam with
2.3% in 2000 [28]. Likely, co-morbidity has influenced
the differences in study findings from Vietnam compared
with Canada [9]. In Vietnam, the HIV-prevalence was low
during the study period [15]. More than 60% of HIV-
infections occurred among people aged < 35 [29]. How-
ever, after excluding tuberculosis patients aged < 35 years
associations were very similar. Therefore, our findings are
not representative for settings with high HIV prevalence.
Higher sputum grade at diagnosis was associated with
higher mortality in India [30], but not in this study. Sub-
jects with a sputum smear graded as scanty may have been
immune compromised and therefore may have higher
risk of mortality. However, scanty sputum smear results
did not explain the tendency towards a declining trend of
mortality with longer delays.
Another explanation for the lack of association between
diagnostic delay and fatality may be the short diagnostic
delay in Vietnam as compared to other countries [16].
Possibly, tuberculosis fatality is increased if disease dura-
tion has been sufficient for cavity formation with associ-
ated lung damage, and chemotherapy cannot overcome
this damage anymore. The time needed for such severe
damage may be much longer than 9 weeks. Whether high
fatality can be used as indicator for long diagnostic delays
in settings with long delays, needs investigation.
The study limitations include patient selection and data
validity. Amongst the excluded patients were patients reg-
istered with treatment default or transfer-out. Some of
these patients could have had died within 8 months, i.e.
the duration of chemotherapy [31]. If all these patients
had died, fatality would have been 74 (7.7%) for those
with delay ≤ 4 weeks, 35 (7.2%) for those with 4- ≤ 8
weeks and 29 (7.2%) for those with > 9 weeks delay.
Therefore, it is unlikely that this seriously biased the
results.
Case fatality rates were based on registered treatment out-
comes and deaths could have been underreported. A fol-
low-up study in northern Vietnam on survival and relapse
or patients with a registered treatment outcome of cure or
treatment completion did not reveal underreporting of
death [32]. It was therefore concluded that treatment suc-
cess was accurately recorded. Even if some cured patients
were in fact treatment failures, then in our analyses, both
cured and failures were analysed as survivors and would
therefore not have biased the results. Furthermore, it is
unlikely that reporting of death depends on delay. If death
was underreported, it is probably non-differential for
delay and it would not have biased the results.
No gold standard exists for valid assessment of diagnostic
delay. The duration of illness as recalled by the patient
may not be accurate, and misclassification in delay catego-
ries can have occurred. This would have resulted in a
diluted association between diagnostic delay and mortal-
ity. Especially among those who reported extreme delays,
recall bias may have played a role. However, extreme
delays did not explain the observed trend towards declin-
ing mortality with longer delays.
Our findings cannot be extrapolated to patient groups
who were not included in the study. These groups are
patients who were diagnosed with tuberculosis but did
not start treatment, and patients treated in provincial and
national tuberculosis hospitals. This does not undermine
the importance of our findings, as in programme evalua-
tions the indicator of case fatality is not used on (non-
existent) data of patients who did not start treatment.
Our findings cannot be applied to settings with high HIV
prevalence or high co-morbidity among tuberculosis
patients, such as in low incidence tuberculosis countries.
However, in these settings high case fatality does probably
not reflect long delays. Our findings imply that in routine
practice in settings with a high burden of tuberculosis a
high case fatality does also not reflect long diagnostic
delays.
Conclusion
Diagnostic delay is not associated with mortality during
tuberculosis treatment in ambulant programmatic set-
tings in Vietnam. This suggests that for such settings high
case fatality should not be used as an indicator of long
diagnostic delay.BMC Public Health 2007, 7:210 http://www.biomedcentral.com/1471-2458/7/210
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